MX360640B - Diagnosis e imagenologia de cancer. - Google Patents

Diagnosis e imagenologia de cancer.

Info

Publication number
MX360640B
MX360640B MX2012010119A MX2012010119A MX360640B MX 360640 B MX360640 B MX 360640B MX 2012010119 A MX2012010119 A MX 2012010119A MX 2012010119 A MX2012010119 A MX 2012010119A MX 360640 B MX360640 B MX 360640B
Authority
MX
Mexico
Prior art keywords
imaging
mammal
cell cycle
cancer diagnosis
administering
Prior art date
Application number
MX2012010119A
Other languages
English (en)
Other versions
MX2012010119A (es
Inventor
S Gray Lloyd
Original Assignee
Tau Therapeutics Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics Llc Star filed Critical Tau Therapeutics Llc Star
Publication of MX2012010119A publication Critical patent/MX2012010119A/es
Publication of MX360640B publication Critical patent/MX360640B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00ICT specially adapted for the handling or processing of medical images
    • G16H30/20ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para crear imagen de una enfermedad o condición en un mamífero, que incluye los pasos de: administrar una cantidad terapéuticamente efectiva de un inhibidor de ciclo celular para detener efectivamente la proliferación de células eucarióticas en un punto de control del ciclo celular entre las fases G1 y S, detener la administración del inhibidor de ciclo celular durante un periodo, administrar un marcador el mamífero y crear imagen del mamífero.
MX2012010119A 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer. MX360640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30903010P 2010-03-01 2010-03-01
PCT/US2011/026416 WO2011109262A2 (en) 2010-03-01 2011-02-28 Cancer diagnosis and imaging

Publications (2)

Publication Number Publication Date
MX2012010119A MX2012010119A (es) 2012-09-12
MX360640B true MX360640B (es) 2018-11-09

Family

ID=44542787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010119A MX360640B (es) 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer.

Country Status (14)

Country Link
US (1) US9427429B2 (es)
EP (1) EP2542155B1 (es)
JP (1) JP6017964B2 (es)
KR (1) KR101821343B1 (es)
CN (1) CN102781316B (es)
AU (1) AU2011223883B2 (es)
CA (1) CA2787673A1 (es)
ES (1) ES2557407T3 (es)
HK (1) HK1179143A1 (es)
IL (1) IL221035A0 (es)
MX (1) MX360640B (es)
SG (2) SG183114A1 (es)
WO (1) WO2011109262A2 (es)
ZA (1) ZA201205377B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778619B1 (en) * 2004-08-20 2012-04-04 University Of Virginia Patent Foundation T type calcium channel inhibitors
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
EP3487516A1 (en) * 2016-07-19 2019-05-29 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2018221722B2 (en) 2017-02-15 2022-02-03 Cavion, Inc. Calcium channel inhibitors
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219609A (en) 1968-07-19 1971-01-20 Koninklijke Pharma Fab Nv Diphenylmethoxyethylamino derivatives
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4091103A (en) 1976-06-23 1978-05-23 Ciba-Geigy Corporation Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives
JPS59161392A (ja) 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
FR2601366B1 (fr) 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
ATE128623T1 (de) 1988-08-02 1995-10-15 Nissan Chemical Ind Ltd Mittel zur verbesserung von arzneimitteleffekten für antitumormittel.
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
FR2636946B1 (fr) 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0467435A3 (en) 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6413967B1 (en) 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
EP0848614B1 (en) 1995-09-08 2006-04-26 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins
ATE256110T1 (de) 1995-09-15 2003-12-15 Neurosearch As Piperindinverbindungen als calcium-kanal-blocker
SK109198A3 (en) 1996-02-14 1999-06-11 Isis Pharmaceuticals Inc Sugar-modified gapped oligonucleotides
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6191156B1 (en) 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
ES2274588T3 (es) 1997-12-03 2007-05-16 MERCK & CO., INC. Composiciones de los canales de calcio a baja tension y procedimientos correspondientes.
EP1036170A1 (en) 1997-12-05 2000-09-20 Loyola University Of Chicago T-type voltage-gated calcium channels and method of using same
JPH11246417A (ja) 1998-03-04 1999-09-14 Nissan Chem Ind Ltd 糖尿病性腎症治療用医薬組成物
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2000015845A1 (en) 1998-08-26 2000-03-23 South Alabama Medical Science Foundation T-type calcium channel
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
CA2369588C (en) 1999-04-07 2011-02-08 Lloyd S. Gray Anticancer calcium channel blockers
US6946475B1 (en) 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
US7195783B2 (en) 1999-07-09 2007-03-27 Fx Life Sciences International Gmbh Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1392361A4 (en) * 2001-05-11 2009-08-05 Univ Texas THERAPY BASED ON ANTI-CD26 MONOCLONAL ANTIBODIES AGAINST DISORDERS ASSOCIATED WITH CELLS EXPRESSING CD26
AU2002328945A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
HU229452B1 (en) 2002-01-17 2013-12-30 Univ British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA2486622A1 (en) 2002-05-20 2003-12-04 Research Development Foundation Aerosol drug inhibition of lung metastases
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10227511A1 (de) 2002-06-19 2004-01-08 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2499599A1 (en) 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
RU2326886C2 (ru) 2003-03-28 2008-06-20 Ниссан Кемикал Индастриз, Лтд. Блокатор кальциевых каналов т-типа
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
JP2008501633A (ja) 2004-02-11 2008-01-24 ユニバーシティ オブ ヴァージニア パテント ファウンデーション 癌の診断及び治療のためのCav3アイソフォーム及びそのδ25スプライスバリアントの阻害
AU2011203315B8 (en) 2004-02-11 2012-02-16 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
US20070178462A1 (en) 2004-02-18 2007-08-02 Uebele Victor N Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20060003020A1 (en) 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2006003020A1 (en) 2004-07-02 2006-01-12 L'oreal Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof
US20080194669A1 (en) 2004-08-20 2008-08-14 Gray Lloyd S T Type Calcium Channel Blockers and the Treatment of Diseases
US20120264804A1 (en) 2004-08-20 2012-10-18 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US20100222406A1 (en) 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
EP1778619B1 (en) 2004-08-20 2012-04-04 University Of Virginia Patent Foundation T type calcium channel inhibitors
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 T-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
BRPI0716498A2 (pt) * 2006-08-10 2015-01-27 Oncotherapy Science Inc Genes e polipeptídeos relacionados a cânceres de mama
CN101528768A (zh) * 2006-08-10 2009-09-09 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
KR20090097188A (ko) 2006-12-19 2009-09-15 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegh-특이적 길항제
WO2008137107A1 (en) 2007-05-02 2008-11-13 Krouse Andrew J Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
JP5029328B2 (ja) 2007-12-05 2012-09-19 マツダ株式会社 自動車の前部車体構造
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
SI2307051T1 (sl) 2008-07-08 2015-04-30 Oncomed Pharmaceuticals, Inc. Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
SG10201402863PA (en) 2009-06-05 2014-10-30 Tau Therapeutics Llc Interlaced method for treating cancer or a precancerous condition
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
SG11201400526TA (en) 2011-09-12 2014-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells

Also Published As

Publication number Publication date
SG10201501496TA (en) 2015-04-29
IL221035A0 (en) 2012-09-24
AU2011223883B2 (en) 2015-10-08
JP2013521287A (ja) 2013-06-10
WO2011109262A3 (en) 2011-11-17
MX2012010119A (es) 2012-09-12
SG183114A1 (en) 2012-09-27
ES2557407T3 (es) 2016-01-25
EP2542155B1 (en) 2015-11-04
CN102781316A (zh) 2012-11-14
KR101821343B1 (ko) 2018-01-23
US20120321561A1 (en) 2012-12-20
US9427429B2 (en) 2016-08-30
CN102781316B (zh) 2016-07-06
AU2011223883A1 (en) 2012-09-13
JP6017964B2 (ja) 2016-11-02
HK1179143A1 (zh) 2013-09-27
ZA201205377B (en) 2013-09-25
WO2011109262A2 (en) 2011-09-09
KR20130014506A (ko) 2013-02-07
CA2787673A1 (en) 2011-09-09
EP2542155A4 (en) 2013-07-17
EP2542155A2 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
MX360640B (es) Diagnosis e imagenologia de cancer.
WO2013033396A3 (en) Fap-activated proteasome inhibitors for treating solid tumors
MX2019002774A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica.
MX2022002786A (es) Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX2019013263A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de enfermedades hepaticas colestasicas pediatricas.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL223889B (en) Contrasting side effects associated with the administration of an anti-hyaluronan factor and methods for alleviating or preventing the side effects
MX2011012940A (es) Metodo entrelazado para tratar cancer o una condicion precancerosa.
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
MX2019009539A (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).
EP2575596A4 (en) METHODS FOR DETERMINING RENEWAL OF BETA-AMYLOIDS IN BLOOD
GB2451987A (en) Assessment of the effects of topical administration of chemodenervating pharmaceuticals
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
PH12014500990A1 (en) Methods for treating gout flares
UA114699C2 (uk) Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
SG195127A1 (en) Methods of treating or preventing neurological diseases
SG195170A1 (en) Methods of treating or preventing rheumatic disease
GB201022049D0 (en) Methods
WO2014169011A3 (en) Methods for treating immune diseases

Legal Events

Date Code Title Description
FG Grant or registration